Sangamo Therapeutics, Inc. (SGMO) Report Analysis
Corporate Events
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell 3000E Value Index
2022-06-24 00:00:00
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell 3000E Value Index
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell 3000E Growth Index
2022-06-24 00:00:00
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell 3000E Growth Index
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell Microcap Value Index
2022-06-24 00:00:00
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell Microcap Value Index
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell Microcap Growth Index
2022-06-24 00:00:00
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell Microcap Growth Index
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell 3000E Index
2022-06-24 00:00:00
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell 3000E Index
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell Microcap Index
2022-06-24 00:00:00
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) added to Russell Microcap Index
Sangamo Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 09:00 AM
2022-06-03 06:32:00
Sangamo Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 09:00 AM. Venue: Marriott Marquis, New York City, New York, United States.
Sangamo Therapeutics, Inc. Presents at BIO International Convention 2022, Jun-13-2022
2022-05-15 00:00:00
Sangamo Therapeutics, Inc. Presents at BIO International Convention 2022, Jun-13-2022 . Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Isaac Young, Senior Director, GXP Procurement & Supplier Management.
Sangamo Therapeutics, Inc. Presents at The 25th Annual Meeting of the American Society Of Gene And Cell Therapy (ASGCT) 2022, May-17-2022 04:00 PM
2022-05-04 19:44:00
Sangamo Therapeutics, Inc. Presents at The 25th Annual Meeting of the American Society Of Gene And Cell Therapy (ASGCT) 2022, May-17-2022 04:00 PM. Venue: Walter E. Washington Convention Center, Washington, District Of Columbia, United States.
Sangamo Therapeutics, Inc. to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2022-05-02 20:30:00
Sangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progression of Sangamo’s pre-clinical programs emerging from its genomic engineering platform. Data to be presented at the ASGCT Annual Meeting include an oral presentation of a study looking at Sangamo’s innovative genetically engineered adeno-associated virus (AAV) capsid platform for delivery to the central nervous system (CNS) after cerebrospinal fluid administration. With protection from the blood-brain barrier, current gene delivery to the CNS continues to be an obstacle. Sangamo’s AAV capsids are designed to overcome that barrier, providing broad CNS access while minimizing exposure to a patient’s pre-existing anti-AAV antibodies. Another Sangamo AAV capsid presentation will outline CNS delivery via intravenous administration. Other presentations at the ASGCT Annual Meeting will showcase how Sangamo is advancing its proprietary zinc finger platform development efforts, including its high-efficiency base-editing program in human cells and its use of zinc finger transcription factors for multiplex engineering of CAR-T cells without imparting changes to the genetic code. Sangamo will also present data from its CAR-Treg cell therapy platform, including outlining advancements in pre-clinical allogeneic Treg engineering.
Sangamo Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022
2022-04-28 20:15:00
Sangamo Therapeutics, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022
Sangamo Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
2022-04-28 20:15:00
Sangamo Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
Sangamo Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 03:05 PM
2022-04-21 20:30:00
Sangamo Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 03:05 PM. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.
Sangamo Therapeutics, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM
2022-04-21 20:30:00
Sangamo Therapeutics, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
Sangamo Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022 through Apr-21-2022
2022-04-12 05:58:00
Sangamo Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mediterranean, Apr-19-2022 through Apr-21-2022. Venue: Barcelona, Spain. Presentation Date & Speakers: Apr-21-2022, D. Mark McClung, Executive VP & COO, Nina Vas, Vice President, Global Clinical Trial Distribution Service.
Sangamo Therapeutics, Inc. - Shareholder/Analyst Call
2022-04-01 20:10:00
2022 Annual Meeting of Stockholders
Sangamo Therapeutics, Inc., Annual General Meeting, May 24, 2022
2022-04-01 20:10:00
Sangamo Therapeutics, Inc., Annual General Meeting, May 24, 2022, at 08:30 Pacific Standard Time. Agenda: To elect the seven nominees for director named in the accompanying proxy statement, or the Proxy Statement, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2023 and until their successors are duly elected and qualified; to approve, on an advisory basis, the compensation of named executive officers, or NEOs, as described in the accompanying Proxy Statement; to approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of its common stock reserved for issuance under the 2018 Plan by 7,900,000 shares; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2022 and to transact such other business as may properly come before the meeting.
Saira Ramasastry Decides Not to Stand for Re-Election as A Member of the Board of Directors of Sangamo Therapeutics, Inc
2022-04-01 20:06:00
On March 28, 2022, Saira Ramasastry, a member of the Board of Directors of Sangamo Therapeutics, Inc. since June 2012, notified the Company of her decision not to stand for re-election at the Company’s annual meeting of stockholders to be held on May 24, 2022.
Sangamo Therapeutics, Inc. Presents at International Conference for Lymphocyte Engineering 2022, Apr-01-2022 12:50 PM
2022-03-29 21:50:00
Sangamo Therapeutics, Inc. Presents at International Conference for Lymphocyte Engineering 2022, Apr-01-2022 12:50 PM.
Sangamo Therapeutics, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022
2022-03-29 20:00:00
Sangamo Therapeutics, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Louise Wilkie, VP, Global Corp. Communications & Investor Relations, Prathyusha Duraibabu, Senior VP, CFO & Principal Accounting Officer, Sandy Macrae, President & CEO.
Sangamo Therapeutics, Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
2022-03-29 12:05:00
Sangamo Therapeutics, Inc. announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. Kidney transplantation is the treatment of choice for patients with end-stage renal disease (ESRD) who must otherwise remain on long-term dialysis. Approximately 21-26% of transplanted kidneys are estimated to be HLA-A2 mismatched. To prevent graft rejection, transplanted patients are treated with lifelong immunosuppressive therapy, which impacts the body’s immune system and is associated with multiple side effects, including an increased risk of severe life-threatening infections, malignancies, cardiovascular disease, and other drug-related toxicities, such as nephrotoxicity, which can impact the function and survival of the newly transplanted kidney. TX200 was designed with the potential to prevent kidney rejection by reducing local inflammation and promoting immunological tolerance to the graft. TX200 is composed of autologous Treg cells engineered to express an HLA-A2 CAR. This investigational cell therapy is being assessed in HLA-A2 negative patients receiving a mismatched HLA-A2 positive kidney from a living donor. TX200 cells are expected to localize to the graft and activate upon binding to the HLA-A2 antigen. Through their ability to regulate the immune system, TX200 cells may protect the graft from immune-mediated rejection and reduce or eliminate the need for lifelong treatment with immunosuppressants. In the STEADFAST clinical study, each patient undergoes a leukapheresis procedure to collect their white blood cells, after which their Treg cells are isolated, genetically engineered and then cryopreserved. The patient subsequently undergoes transplantation surgery to receive a kidney from a living donor. Following a recovery period, the patient receives their personalized TX200 investigational cell therapy. Dosing of patients therefore occurs several months after patient enrollment. Sangamo expects to dose a second patient in the STEADFAST study in the middle of 2022. The STEADFAST study forms the first step in a pipeline of CAR-Treg programs. In addition to TX200, Sangamo is developing CAR-Treg cell therapy candidates in preclinical studies, including for potential use in treating multiple sclerosis and inflammatory bowel disorders.
Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022
2022-03-29 11:02:00
Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.
Sangamo Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 12:00 PM
2022-03-22 05:03:00
Sangamo Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 12:00 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Alexander D. Macrae, CEO, President & Director.
American Society of Gene & Cell Therapy, the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) 2022, May 16, 2022 through May 19, 2022
2022-03-17 20:15:00
American Society of Gene & Cell Therapy, The 25th Annual Meeting of the American Society Of Gene And Cell Therapy (ASGCT) 2022, May 16, 2022 through May 19, 2022. Venue: Walter E. Washington Convention Center, Washington, District Of Columbia, United States.
RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022
2022-03-04 01:06:00
RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.
Sangamo Therapeutics, Inc. Presents at HC Wainwright Gene Therapy and Gene Editing Conference 2022, Mar-30-2022 07:00 AM
2022-02-28 22:00:00
Sangamo Therapeutics, Inc. Presents at HC Wainwright Gene Therapy and Gene Editing Conference 2022, Mar-30-2022 07:00 AM.
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022
2022-02-28 18:21:00
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
Global Education of Medicine and Science, International Conference for Lymphocyte Engineering 2022, Mar 31, 2022 through Apr 02, 2022
2022-02-26 07:53:00
Global Education of Medicine and Science, International Conference for Lymphocyte Engineering 2022, Mar 31, 2022 through Apr 02, 2022.
Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022
2022-02-26 07:53:00
Alliance for Regenerative Medicine, Cell & Gene Meeting on the Mediterranean, Apr 19, 2022 through Apr 21, 2022. Venue: Barcelona, Spain.
H.C. Wainwright & Co., LLC, HC Wainwright Gene Therapy and Gene Editing Conference 2022, Mar 30, 2022
2022-02-24 12:30:00
H.C. Wainwright & Co., LLC, HC Wainwright Gene Therapy and Gene Editing Conference 2022, Mar 30, 2022.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Sangamo Therapeutics, Inc. Presents at 18th Annual WORLDSymposium, Feb-08-2022 10:30 AM
2022-02-07 23:00:00
Sangamo Therapeutics, Inc. Presents at 18th Annual WORLDSymposium, Feb-08-2022 10:30 AM. Venue: San Diego, California, United States.
Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Patients with Fabry Disease
2022-02-07 23:00:00
Sangamo Therapeutics, Inc. announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest data show that, as of the November 9, 2021 cutoff date, the investigational treatment continued to be well tolerated and that the four longest treated patients continued to exhibit elevated alpha-galactosidase A (a-Gal A) activity. These data are being presented at the 18th Annual WORLDSymposiumTM in a platform presentation on February 8, 2022 during the 1:30 p.m. Eastern Time session and in a poster presentation available on February 7, 2022 at 6:00 p.m. Eastern Time. As of the cutoff date, elevated a-Gal A activity was maintained for the four patients treated in the first two dose cohorts (0.5e13 vg/kg and 1e13 vg/kg) ranging from 3-fold to 15-fold above mean normal at last measurement. For the two patients on enzyme replacement therapy (ERT), a-Gal A activity measured at ERT trough was 15-fold above mean normal at week 52 (Cohort 1) and 10-fold above mean normal at week 25 (Cohort 2). For the two ERT pseudo-naïve patients, a-Gal A activity was 3-fold above mean normal at week 52 (Cohort 1) and 4-fold above mean normal at week 40 (Cohort 2). The two patients in the first dose cohort have now begun the long-term follow-up study. For the first patient in the third dose cohort (3e13 vg/kg), a-Gal A activity has increased into mean normal range at week 2. Withdrawal from ERT has been completed for one patient and is planned for the other patient on ERT, based on the stability of their a-Gal A activity following treatment. As of the cutoff date, isaralgagene civaparvovec was generally well tolerated across three dose cohorts in the five treated patients. There were no treatment-related adverse events higher than Grade 1 (mild) and no treatment-related serious adverse events. No patients experienced liver enzyme elevations requiring steroid treatment. Improvements in ability to sweat were reported in the first three treated patients. No progression of Fabry cardiomyopathy was observed in the two patients experiencing cardiomyopathy prior to treatment. The one patient with a significant elevation in plasma globotriaosylsphingosine (lyso-Gb3) pre-treatment showed a significant reduction of approximately 40% (from baseline within 10 weeks after dosing, maintained through Week 36) in this biomarker after treatment with isaralgagene civaparvovec. Patients with lower baseline levels of lyso-Gb3 maintained steady levels through the cutoff date. The sixth patient in the Phase 1/2 STAAR study, who is the second patient in the third dose cohort (3e13 vg/kg), was recently dosed after the cutoff date. Sangamo expects to provide updated results from the STAAR study throughout 2022. Sangamo is currently planning for a Phase 3 clinical trial.
WORLDSymposia Ltd, 18th Annual WORLDSymposium, Feb 07, 2022 through Feb 11, 2022
2022-01-18 10:00:00
WORLDSymposia Ltd, 18th Annual WORLDSymposium, Feb 07, 2022 through Feb 11, 2022. Venue: San Diego, California, United States. To discuss lysosomal storage diseases.
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
2021-12-12 14:00:00
Sangamo Therapeutics, Inc. announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease (SCD). These data are being presented at the 63rdAmerican Society for Hematology Annual Meeting and Exposition taking place from December 11-14 virtually and in Atlanta, GA. The poster presentation, which includes follow-up data up to 91 weeks for the longest-treated patient, is available on Sangamo’s website in the Investors and Media section under Events and Presentations. As of the September 22, 2021 cutoff date, the most recently treated patient in the PRECIZN-1 Phase 1/2 study had been followed for 26 weeks and the longest-treated patient had been followed for 91 weeks. None of the four treated patients required blood transfusions post engraftment. Total hemoglobin stabilized by Week 26 after treatment with SAR445136 in all four patients. Fetal hemoglobin level increased from 0.1-11% at screening to 14-39% by Week 26 in all four patients and was 38% in the longest-treated patient at 91 weeks. Percent F cells increased to 64%-96% by 39 weeks of follow-up in all four patients, persisting at 99% in the patient with 91 weeks of follow-up. The SAR445136 investigational drug product had on-target BCL11A gene modification (61-78%) in all four patients.
Sangamo Therapeutics, Inc. Announces Board Changes, Effective March 1, 2022
2021-11-22 11:05:00
On November 17, 2021, Joseph S. Zakrzewski, a member of the Board of Directors (the Board") of Sangamo Therapeutics, Inc. notified the Company of his voluntary resignation from the Board effective March 1, 2022. Mr. Zakrzewski's resignation is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022
2021-11-09 17:12:00
Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Center, San Diego, California, United States.
Sangamo Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 03:20 PM
2021-11-09 13:30:00
Sangamo Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 03:20 PM. Venue: New York, New York, United States.
Sangamo Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 08:40 AM
2021-11-09 13:30:00
Sangamo Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 08:40 AM. Venue: London, United Kingdom.
Sangamo Therapeutics, Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2021, Nov-15-2021 10:30 AM
2021-11-09 13:30:00
Sangamo Therapeutics, Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2021, Nov-15-2021 10:30 AM.
Sangamo Therapeutics, Inc. Appoints D. Mark Mcclung as Chief Operating Officer
2021-11-04 13:06:00
Sangamo Therapeutics, Inc. appointed D. Mark McClung as Chief Operating Officer.
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Patients with Fabry Disease
2021-11-04 12:00:00
Sangamo Therapeutics, Inc. announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. As of the September 17, 2021 cutoff date, results from the four patients treated in the first two dose cohorts (0.5e13 vg/kg and 1e13 vg/kg) showed that isaralgagene civaparvovec was generally well tolerated. All four patients exhibited above normal alpha-galactosidase A (a-Gal A) activity, which was maintained for up to one year for the first patient treated and through 14 weeks for the most recently treated patient. Activity of 2-fold to 15-fold above mean normal was observed at last measurement as of the cutoff date. Withdrawal from enzyme replacement therapy (ERT) has taken place for one patient and is planned for the other patient on ERT, based on the stability of their a-Gal A activity following treatment. As of the cutoff date, there were no treatment-related adverse events higher than Grade 1 (mild) and no treatment-related serious adverse events. No patients experienced liver enzyme elevations requiring steroid treatment. The one patient with a significant elevation in plasma lyso-Gb3 pre-treatment showed significant reductions of approximately 40% (from baseline within 10 weeks after dosing, maintained through Week 32) in this biomarker after treatment with isaralgagene civaparvovec. Patients with low baseline levels of lyso-Gb3 maintained steady levels through the cutoff date. The fifth patient in the Phase 1/2 STAAR study, who is the first patient in the third cohort (3e13vg/kg), was dosed after the cutoff date. The sixth patient is currently in screening, also for the third dose cohort. Sangamo expects to provide updated results from the STAAR study throughout 2022 and present these results at a medical meeting.
Sangamo Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021
2021-10-28 20:55:00
Sangamo Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021
Sangamo Therapeutics, Inc. to Report Q3, 2021 Results on Nov 04, 2021
2021-10-28 20:55:00
Sangamo Therapeutics, Inc. announced that they will report Q3, 2021 results on Nov 04, 2021
Sangamo Therapeutics, Inc. Enters into Amended and Restated Office/Laboratory Lease with Point Richmond R&D Associates II, LLC
2021-10-22 20:05:00
On October 18, 2021, Sangamo Therapeutics, Inc. entered into an Amended and Restated Office/Laboratory Lease (Lease) with Point Richmond R&D Associates II, LLC (Landlord) for the lease of approximately 51,488 square feet of rentable area of the building located at 501 Canal Boulevard, Point Richmond, California (Premises), which the Company currently occupies and utilizes as research and office space. The initial term of the Lease runs from October 1, 2021 through August 31, 2031 (Initial Term), extending the expiration date of the Company’s preexisting lease for the Premises for an additional five years. In addition, the Company will lease an additional 7,997 square feet of office space at the same location (together with the Premises, the Combined Premises) from November 1, 2021 through the expiration of the Initial Term. Monthly base rent for the Combined Premises will escalate from approximately $125,275, the base rent for the month of October 2021, to approximately $187,250 over the course of the Initial Term. The aggregate estimated rent payments due over the Initial Term of the Lease is approximately $19.6 million. The Landlord will contribute approximately $2.6 million during the Initial Term toward tenant improvements. Subject to certain conditions, Sangamo shall have the option to extend the Term of the Lease one time for an additional period of 60 months (Extension Option). The Extension Option will be upon the same material terms and conditions as the Lease, except that the initial monthly base rent for the Combined Premises will be equal to the greater of the then-prevailing market rent as determined pursuant to the terms of the Lease and the monthly base rent in effect as of the expiration of the Initial Term, in each case subject to a 3% annual increase during the term of the Extension Option.
Barclays PLC, Barclays Gene Editing & Gene Therapy Summit 2021, Nov 15, 2021 through Nov 16, 2021
2021-10-20 20:00:00
Barclays PLC, Barclays Gene Editing & Gene Therapy Summit 2021, Nov 15, 2021 through Nov 16, 2021.
Sangamo Therapeutics, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 12:00 PM
2021-09-28 18:44:00
Sangamo Therapeutics, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 12:00 PM. Speakers: Alexander D. Macrae, CEO, President & Director.
Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021
2021-09-28 13:09:00
Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.
Sangamo Therapeutics, Inc. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021
2021-09-16 14:42:00
Sangamo Therapeutics, Inc. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021 . Speakers: Santosh kumar Khatwani, Associate Director, Analytical Development.
Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021
2021-09-08 23:01:00
Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021.
Sangamo Therapeutics, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-08-31 12:30:00
Sangamo Therapeutics, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.
Sangamo Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 10:15 AM
2021-08-31 12:30:00
Sangamo Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 10:15 AM. Venue: New Windsor, United States.
Sangamo Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:55 PM
2021-08-09 20:30:00
Sangamo Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:55 PM.
Sangamo Therapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
2021-07-29 20:30:00
Sangamo Therapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
Sangamo Therapeutics, Inc. to Report Q2, 2021 Results on Aug 05, 2021
2021-07-29 20:30:00
Sangamo Therapeutics, Inc. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021
Sangamo Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 through Oct-14-2021
2021-07-29 02:31:00
Sangamo Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 through Oct-14-2021. Venue: Carlsbad, California, United States. Presentation Date & Speakers: Oct-12-2021, D. Mark McClung, Executive VP & Chief Business Officer, Sandy Macrae, President and CEO. Oct-13-2021.
Sangamo Therapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 03:20 PM
2021-07-22 14:24:00
Sangamo Therapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 03:20 PM. Speakers: Alexander D. Macrae, CEO, President & Director, D. Mark McClung, Executive VP & Chief Business Officer.
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021
2021-07-22 09:08:00
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021
2021-07-08 08:44:00
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.
Sangamo Therapeutics, Inc. Announces Resignation of Gary H. Loeb as Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
2021-07-01 20:31:00
On June 28, 2021, Gary H. Loeb, Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer of Sangamo Therapeutics, Inc., notified the Company of his resignation from these positions and from his employment with the Company, in each case to be effective on July 16, 2021, in order to pursue a new opportunity.
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021
2021-06-29 20:28:00
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.
Fundamental Summary
Sangamo Therapeutics's recently released results from Q1 indicate that Sangamo Therapeutics is performing reasonably well and on par with its peers. Its growth and income factors appear positive and give support for optimism regarding the likelihood of continued positive performance. Therefore, Sangamo Therapeutics received an overall score of 65, translating into a HOLD ranking.
Sangamo Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 28.23 million compared to USD 26.28 million a year ago. Net loss was USD 43.98 million compared to USD 45.93 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.32 a year ago. Diluted loss per share from continuing operations was USD 0.3 compared to USD 0.32 a year ago.
Business Description
Sangamo Therapeutics, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson’s disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics in January 2017. Sangamo Therapeutics was incorporated in 1995 and is headquartered in Brisbane, California.
Sector Overview
Sangamo Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Sangamo Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -43.9 | -7.4% | 73 | |
| Net Cashflow | -2.7 | -105.7% | 85 | |
| Capital Expenditure | -18.2 | 22.0% | 93 | |
| Asset Turnover | 0.1 | 10.3% | 83 | |
| Free Cashflow | -1.7 | 6.2% | 78 |
* All values are TTM
The below chart reflects Sangamo Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Sangamo Therapeutics's peer average final assessment score stands on 60.0, Sangamo Therapeutics's score is 65.
- SGMO
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Sangamo Therapeutics's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Sangamo Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.
5D MA
4.21
50D MA
4.04
200D MA
6.58
MACD
0.03
RSI
9.78
STOCH
74.31
Balance Sheet Analysis
Sangamo Therapeutics's balance sheet factors had several troubling metrics this period. Sangamo Therapeutics's management did a relatively poor job managing cash and cash equivalents, which now sit at 120.3 and represents a -32.8% change from the last reporting period. Their anemic growth in cash and cash equivalents, specifically in contrast to their industry peers' performance, should hurt their stock price. Its cash and cash equivalents movement, therefore, received a grade of 45. Also, Sangamo Therapeutics publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 1.8 and represents -39.6% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Consequently, their book value factors movement received a grade of 46. However, one encouraging metric, Assets, stood out. Sangamo Therapeutics's management was effective in managing the value of the assets on their balance sheet, which now sits at 654.3 and represents a -9.4% change from the previous report. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their asset movement received a grade of 64. Consequently, their balance sheet earned a rank of 48.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 654.3 | -9.4% | 64 |
| Liabilities | 319.8 | -7.7% | 59 |
| Price to Book | 1.8 | -39.6% | 46 |
| Cash & Equivalents | 120.3 | -32.8% | 45 |
| Equity | 334.5 | -10.9% | 47 |
The below chart describes Sangamo Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Sangamo Therapeutics received a balance sheet score of 48, the average of its peers stands on 60.0.
- SGMO
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 16 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 18 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 20 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 23 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 38 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Return Factors and EBITDA stand out as the most significant drivers of Sangamo Therapeutics's income statement's strength. In this filing, Sangamo Therapeutics reported a return on equity (ROE) ratio of -43.9, which represents a change of -7.4%. Its return factor metrics are even more remarkable when compared to their peers. Therefore, its return factors component earned a score of 73. Also, Sangamo Therapeutics reported impressive EBITDA this period. At filing, EBITDA was reported as -158.2, representing 1.3% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Consequently, their EBITDA movement received a grade of 72. On the other hand, EBITDA, jumped out as looking rather underwhelming. Sangamo Therapeutics's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -158.2, which represents a 1.3% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Their EBITDA metrics are even more problematic when compared to their peers. Its EBITDA movement, therefore, received a grade of 72. Therefore, we scored its income statement a 76.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -158.2 | 1.3% | 72 |
| Total Revenues | 112.7 | 1.8% | 72 |
| Return on Equity | -43.9 | -7.4% | 73 |
The below chart describes Sangamo Therapeutics's performance as reflected on its income statement with respect to its peers. While Sangamo Therapeutics received a income statement score of 76 , the average of its peers stands on 63.0.
- SGMO
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 16 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 18 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 23 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 38 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Sangamo Therapeutics appears likely to maintain its strong cash flow metrics and momentum going forward. Sangamo Therapeutics's management was effective in improving its CapEx, which now sits at -18.2 and represents 22.0% change from the previous report. This performance is all the more impressive relative to their peers and competitors. Consequently, their CapEx movement received a grade of 93. Also, Sangamo Therapeutics's management was effective in improving their net cash flow, which now sits at -2.7 and represents a -105.7% change from the previous report. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. The company's net cash flow, therefore, received a grade of 85. On the other hand, Free Cash flow, jumped out as looking problematic. Sangamo Therapeutics did a poor job related to generating and maintaining strong free cash flow this period, which stood at -1.7, representing a 6.2% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is more concerning relative to their peers and competitors. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 78. The company's cash flow received an overall score of 91.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -2.7 | -105.7% | 85 |
| Capital Expenditure | -18.2 | 22.0% | 93 |
| Asset Turnover | 0.1 | 10.3% | 83 |
| Free Cashflow | -1.7 | 6.2% | 78 |
The below chart describes Sangamo Therapeutics's performance as reflected on its cash flow with respect to its peers. While Sangamo Therapeutics received a cash flow score of 91, the average of its peers stands on 66.0.
- SGMO
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 16 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 18 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 23 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 38 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.